Company ProfilePremium

Novartis International AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Novartis International AG - Healthcare showcase

Year Founded & Workforce

1966

108,000 Employees

Industry

Healthcare

Services

Dercum’s Disease Market
N

Novartis International AG Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Novartis International AG Overview

Company Headquarters: Basel, Switzerland

Founded: 1966

Workforce: ~108,000

Company Working: Novartis International AG (Novartis) is engaged in the production of pharmaceutical drugs. It is a fully integrated life sciences company that provides research, product development, manufacturing, and distribution of products. It is an outstanding worldwide source of regenerative medicine technology, clinical research, education, and training for the constantly evolving healthcare industry. It ranks among the world’s top companies investing in research and development. It carries out research at Novartis locations and partner institutions worldwide: Cambridge, the US; Basel, Switzerland; East Hanover, US; Emeryville, US; and Shanghai, China. Sandoz, a Novartis division, is a global provider of generic pharmaceuticals and biosimilars.

Strategy

Novartis focuses on continuous innovations in pharmaceutical products. The company also continuously evaluates strategic opportunities to acquire companies, divisions, technologies, products, and rights through licenses, distribution agreements, investments, and acquisitions to grow the business. Its strategy is to use science-based innovation to deliver better patient outcomes. Its focus is to lead in growing areas of the healthcare sector.

Company Snapshot

$47,445M

Revenue

108,000

Employees

$172,750M

Market Cap

1966

Founded

Basel, Switzerland

Headquarters

SWOT Analysis

Strengths

  • Global presence
  • Strong research & development

Weaknesses

  • High dependence on matured markets
  • Rising external business risks

Opportunities

  • New product launches
  • Global penetration through mergers and acquisitions

Threats

  • Rising competition from other companies in emerging markets

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product Offering

  • Novartis International AG
    • Dercum’s Disease Market

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 47,445 Mn in 2019 to USD 51,626 Mn in 2021.
Novartis International AG — By Business Segment
Series (USD Mn)201920202021
Sales47,44548,65951,626
R&D Expenditure9,4028,9809,540

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.